Hemispherx Biopharma and Bioclones, a Leading South African Biotechnology Company, Join Forces on Novel Therapeutic Cancer

Hemispherx Biopharma and Bioclones, a Leading South African Biotechnology
Company, Join Forces on Novel Therapeutic Cancer Vaccine

Builds on Recently Issued Patent Estates of Both Companies and Basic Research
/ Clinical Advancement in Cancer Control

PHILADELPHIA, July 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc.
(NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced a strategic alliance
to develop multiple projects with Bioclones (Pty) Ltd. ("Bioclones"), a
leading South African biotechnology company.

On June 25, 2014, Bioclones and Hemispherx concluded strategic discussions in
Johannesburg with three principle goals; 1) initiating studies utilizing
Ampligen® as a potential adjuvant enhancement of Bioclones' therapeutic cancer
vaccine, currently in clinical trials in Cape Town, including pre-clinical
studies followed, potentially, by a Phase 1 clinical trial; 2) seeking South
African Medicine's Control Council approval to conduct trials using Alferon®
to eradicate the HIV virus in patients highly responsive to anti-retroviral
therapy (HAART); and 3) initiating a joint effort to obtain commercial
registration of bothAmpligen® and Alferon® in the South African markets.

The first clinical program builds on the Bioclones patented (US Patent
7,981,673 entitled "Process for the maturation of dendritic cells and a
vaccine") therapeutic human dendritic cell (DC) cancer vaccination approach.
This invention provides a method of producing mature DCs in vitro, which
comprises the step of culturing the immature DCs, thereafter exposing said
cells to tumor antigens before administration to patients. The team has
successfully obtained the necessary Ethics approval to use Ampligen® as an
adjuvant in the Bioclones pre-clinical cancer immunotherapy program utilizing
patient derived samples. Pre-clinical studies will be directed towards the
potential treatment of breast cancer in particular, followed by prostate
cancer. These studies are part of the effort to develop patient-specific DC
immunotherapy vaccines against breast cancer and prostate cancer, which elicit
an immune response that will target and kill cancer cells. Human DCs matured
with Ampligen® and transfected with autologous tumor-specific mRNA are
designed to elicit a potent and autologous tumoricidal antigen-specific
cytotoxic response to the cancer.

Similar programs were successfully developed in the US at the Dendreon Corp.,
and Hemispherx currently has existing immunotherapy studies in the US at the
University of Pittsburgh Comprehensive Cancer Center and the Georgia Regents
Research Institute.The Bioclones collaboration is designed to enlarge and
enhance the potential clinical results with the US based programs.

Ismet Amod, CEO of Bioclones, stated, "We and the University of Cape Town
based research team led by Kamsellin Chetty are very excited about securing
Ampligen from Hemispherx for the clinical work on dendritic cell vaccine
technology which is an essential component in our novel treatment to fight

The already substantial Hemispherx patent estate related to Ampligen® was
recently expanded with a new composition of matter patent. On May 13, 2014,
the United States Patent Office issued patent US 8,722,874 B2 titled
"Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure and
Highly Specific Biologic Activity" to Hemispherx Biopharma, Inc.The patent
describes a novel form of rugged dsRNA, which is a key component of the
company's experimental drug Ampligen®, and which displays a unique composition
and physical characteristic identified with high specificity of binding to
Toll-Like Receptor 3 (TLR3), thereby conveying an important range of
therapeutic opportunities. The Hemispherx inventors discovered, using highly
sophisticated analytical methods, that within the mixture of Ampligen® RNAs of
different sizes and molecular configurations, a highly specific subset of
molecules – not previously known to exist – in fact convey a
disproportionately higher percentage of the resultant biological activity
believed to be important in the immunotherapeutic response to cancer.

Thomas Equels, Executive Vice Chairman of Hemispherx, stated, "This is another
importantstep forward in the globalization of Hemispherx as well as the
sharing of our important experimental immune system therapies with the
world.We look forward to collaborating with Bioclones, our partner in South
Africa, as we work together to maximize the potential use of Ampligen® and
Alferon® in the treatment of cancers and HIV."

About Bioclones

Bioclones is a South African-owned biotechnology company dedicated to the
manufacture of modern biotechnology products for human pharmaceutical use as
well as the development of biotechnology infrastructure and skills across the
African continent. It was established in 1982 and is the largest biotechnology
company in this field in South Africa.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company
engaged in the manufacture and clinical development of new drug entities for
treatment of seriously debilitating disorders. Hemispherx's flagship products
include Alferon N Injection® and the experimental therapeutics Ampligen® and
Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed
for globally important debilitating diseases and disorders of the immune
system, including Chronic Fatigue Syndrome. Hemispherx's platform technology
includes components for potential treatment of various severely debilitating
and life threatening diseases. Because both Ampligen® and Alferon® LDO are
experimental in nature, they are not designated safe and effective by a
regulatory authority for general use and are legally available only through
clinical trials. Hemispherx has patents comprising its core intellectual
property estate and a fully commercialized product (Alferon N Injection®),
approved for sale in the U.S. and Argentina. The Company's Alferon® N approval
in Argentina includes the use of Alferon N Injection® (under the brand name
"Naturaferon") for use in any patients who fail or become intolerant to
recombinant interferon, including patients with chronic active hepatitis C
infection. The Company wholly owns and exclusively operates a GMP certified
manufacturing facility in the United States for commercial products. For more
information please visit www.hemispherx.net.

Forward-Looking Statements

To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Words such as "intends," "plans," and similar expressions are intended
to identify forward-looking statements. The inclusion of forward-looking
statements should not be regarded as a representation by Hemispherx that any
of its plans will be achieved. These forward-looking statements are neither
promises nor guarantees of future performance, and are subject to a variety of
risks and uncertainties, many of which are beyond Hemispherx's control, which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. Examples of such risks and uncertainties
include those set forth in the Disclosure Notice, below, as well as the risks
described in Hemispherx's filings with the Securities and Exchange Commission,
including the most recent reports on Forms 10-K, 10-Q and 8-K. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof, and Hemispherx undertakes no
obligation to update or revise the information contained in this press
release, whether as a result of new information, future events or
circumstances or otherwise revise or update this release to reflect events or
circumstances after the date hereof.

Disclosure Notice

The information in this press release includes certain "forward-looking"
statements including without limitation statements about additional steps
which the FDA may require and Hemispherx may take in continuing to seek
commercial approval of the Ampligen® NDA for the treatment of Chronic Fatigue
Syndrome in the United States. The final results of these and other ongoing
activities could vary materially from Hemispherx's expectations and could
adversely affect the chances for approval of the Ampligen® NDA in the United
States and other countries. Any failure to satisfy the FDA regulatory
requirements or the requirements of other countries could significantly delay,
or preclude outright, approval of the Ampligen® NDA in the United States and
other countries.

Information contained in this news release, other than historical information,
should be considered forward-looking and is subject to various risk factors
and uncertainties. For instance, the strategies and operations of Hemispherx
involve risk of competition, changing market conditions, changes in laws and
regulations affecting these industries and numerous other factors discussed in
this release and in the Company's filings with the Securities and Exchange
Commission. The final results of these efforts and/or any other activities
could vary materially from Hemispherx's expectations.

CONTACT: Company/Investor Contact:
         Charles Jones
         CJones & Associates Public Relations
         Office: 888-557-6480
         Cell: 305-987-7418
         Email: cjones@cjonespr.com
Press spacebar to pause and continue. Press esc to stop.